Review Article

Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Yun-Jung Choi

Red Cross College of Nursing, Chung-Ang University, 84 Heukseok-Dong, Dongjak-Gu, Seoul 156-756, Republic of Korea

Correspondence should be addressed to Yun-Jung Choi; yunjungchoi@cau.ac.kr

Received 16 July 2014; Revised 2 December 2014; Accepted 11 December 2014

Academic Editor: Dawn I. Velligan

Copyright © 2015 Yun-Jung Choi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patient taking atypical antipsychotics.

Methods. Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis.

Results. Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric evaluations did not show statistically significant changes between treatment groups and placebo groups except topiramate adjunctive treatments. Adverse effects regarding adjunctive therapies were tolerable and showed statistically no significances compared to control groups.

Conclusion. Though having several reports related to exacerbation of psychiatric symptoms, topiramate and aripiprazole are more efficacious than other medications in regard to weight reduction and less burden of critical adverse effects as well as being beneficial for clinical improvement.

1. Introduction

Patients with schizophrenia are predisposed to becoming overweight through lifestyle factors, including sedentary lives, unhealthy diet, and socioeconomic status [1]. Though research into underlying mechanisms has identified some risk factors such as H1 receptor affinity [2] and 5HT2c polymorphisms [3], the pharmacology of antipsychotic-induced weight gain is largely not understood and is very likely multifactorial [4]. In schizophrenia, the estimated prevalence of overweight and obese individuals is 2- to 3-fold that of the general population [5]. Prevention of weight gain and treatment of obesity among patients with schizophrenia taking atypical antipsychotics have become a priority in clinical practice and represent a major public health problem [1, 6]. While switching to a more weight-neutral atypical antipsychotic agent offers promise in halting or reversing weight gain associated with an antipsychotic agent, many patients and their clinicians are reluctant to risk worsening or return of psychotic symptoms [4]. As a result, various agents have been proposed as adjunctive treatments to attenuate antipsychotic-induced weight gain [7].

This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patients taking atypical antipsychotics.

2. Methods

2.1. Identification of Clinical Trials. Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Relevant trials were searched using the following keywords: “weight gain,” “weight loss,” “weight reduction,” “antipsychotics,”...
“atypical,” “schizophrenia,” “adjunctive,” “additional,” “com-

bine,” “coadministration,” “treatment,” “therapy,” “effect,” “effi-
cacy,” and “clinical trial.” Reference lists of retrieved articles

were searched for additional studies. Inclusion criteria for this

research were treatment effectiveness from clinical trials of

adjunctive treatments added on atypical antipsychotics for

adult schizophrenia population and containing outcome data

regarding weight and clinical evaluation. Primary outcomes

included the reduction in weight determined by body weight

(BWT) or body mass index (BMI). Secondary outcomes

included psychiatric symptom evaluations measured by the

brief psychiatric rating scale (BPRS), the positive and negative

syndrome scale (PANSS), or the scale for assessment of

positive symptom (SAPS). The exclusion criteria included

research from nonpharmacological treatments, secondary

data sources, unclear research procedures or outcomes,

subjects with comorbid disorders, and population of chil-

dren or adolescents. Initially, one hundred and thirty-one

trials were retrieved by searching for keywords from the

databases. Ninety-three trials were excluded after evaluation

of abstracts. Full papers of thirty-eight potential trials for

inclusion were reviewed using the Joanna Briggs Institute
data extraction form [5] and twenty-four trials were excluded.

The Joanna Briggs Institute data extraction form was used to

equip the data while reviewing full text paper, which contained

author, source, method, sample size, and interventions of the

study. Remaining fourteen trials were assessed by the Jadad

scale for methodological quality. The Jadad scale was applied

to assess quality of clinical trials. The Jadad scale is comprised

of the following five questions: (1) Is the study randomized?

(2) Is the study double blinded? (3) Is there a description of

withdrawals? (4) Is the randomization adequately described?

(5) Is the blindness adequately described? Each question

demands a yes or no response. A total of five points can

be awarded, and higher scores indicate superior quality [6].

A flow chart of the trial inclusion procedure is provided in

Figure 1.

2.2. Data Extraction and Collation. Primary outcomes

included the Jadad score, atypical antipsychotics as con-

current therapy, type and daily maximum dose of adjunc-
tion, treatment duration, sample size and number of drop,

weight reduction and significance between groups as primary

outcome, and psychiatric symptom evaluation and signifi-
cance between groups as secondary outcome. Efficacies of

adjunctive treatments were compared by primary as well as

secondary outcomes including mean change from baseline.

Meta-analyses were conducted using the Comprehensive

Meta-Analysis version 2 regarding adjunctive treatments with

topiramate, sibutramine, metformin, and reboxetine.

3. Results

Fourteen randomized clinical trials published from 2002 to

2010 were included for this systematic review and meta-
analysis (Table 1). Mean of the Jadad scores was 3.8 out

of 5 (ranged from 5 to 2). Medications for adjunctive

treatments were aripiprazole, topiramate, metformin, sibu-

tramine, reboxetine, famotidine, nizatidine, and fluoxetine.

Adjunctive treatments of famotidine, nizatidine, and fluoxy-
etine exhibited neither reductions of weight nor significances

compared to the placebo groups ($P = 0.91$–$0.36$). Rest of

the adjunctive treatments showed weight reductions from

$-6.8$ to $+5.5$ kg ($P = 0.31$–$<0.001$). Difference in means and

significances from meta-analyses regarding adjunctive treat-
ments were as follows: topiramate ($n = 99$): $-2.405$ kg/m$^2$

($P = 0.004$); sibutramine ($n = 58$): $-2.342$ kg ($P = 0.004$);

metformin ($n = 160$): $-1.331$ kg ($P = 0.014$); reboxetine

($n = 85$): $-1.862$ kg ($P = 0.001$) (Tables 2–5).

Psychiatric evaluations, evaluated by PANSS, BPRS, and

SAPS, did not show statistically significant changes between

treatment groups and placebo groups except topiramate

adjunction ($P \leq 0.001$). Adjunctive treatments of metformin

plus sibutramine on olanzapine brought exacerbation of psy-

chiatric symptoms evaluated by BPRS raised up to 35.4 mean

scores from the baseline. Adverse effects regarding adjunc-
tive therapies were tolerable and showed statistically no

significances compared to control groups. Three participants

among the fourteen trials experienced severe adverse effects,
in aripiprazole adjunctive treatments, such as moderate sinus

tachycardia, severe psychotic disorder, and severe auditory

hallucinations.

4. Discussion

Since the occurrence of dilemma of weight gain in patients

receiving atypical antipsychotics, various efforts have been

tried to solve the problem. Present study shows the trends

of trials by time transition. In the early 2000s, fluoxetine,
nizatidine, and famotidine were examined as choices of

adjunctive treatments for weight control regarding atypical

antipsychotics [17, 18, 20]. However, those combinations

have failed to present consistent weight reduction neither

within the treatment group nor difference between the

groups ($P = 0.36$–$0.91$) [17, 18, 20]. After the middle of the

2000s, reboxetine, sibutramine, and metformin have been

investigated and there have been some degree of rewarding

findings. Recently, topiramate and aripiprazole are added in

the stream of finding a key of weight reduction for patients

taking atypical antipsychotics [6, 9, 10].

Reboxetine is a selective norepinephrine reuptake

inhibitor (NRI) and is a new psychotropic drug broadly used
## Table 1: Characteristics of studies for systematic review and meta-analysis.

| Number | First author | Jadad score | Concurrent therapy | Augmentation (mg/day, daily max. dose) | Duration (weeks) | n (drop) | Primary outcome | Secondary outcome | P | P |
|--------|--------------|-------------|--------------------|-----------------------------------------|------------------|---------|----------------|-------------------|---|---|
| 1      | Fleischhacker (2010) [8] | 4           | Clozapine          | Aripiprazole (15) placebo               | 16               | 108 (0) | BWT            | <0.001            | PANSS 0.37 |
| 2      | Narula (2010) [9] | 3           | Olanzapine         | Topiramate (100) placebo                | 12               | 33 (3)  | BMI            | 0.004             | PANSS 0.00 |
| 3      | Afshar (2009) [10] | 4           | Clozapine          | Topiramate (300) placebo                | 8                | 16 (0)  | BMI            | ≤0.05             | PANSS <0.001 |
| 4      | Baptista (2008) [11] | 4           | Olanzapine         | Metformin (1700) + sibutramine (20) placebo | 12             | 13 (0)  | BWT            | 0.19              | BPRS 0.15 |
| 5      | Wu (2008) [12] | 5           | Olanzapine         | Metformin (750) placebo                 | 12               | 20 (2)  | BWT            | <0.02             | SAPS 0.52 |
| 6      | Baptista (2007) [13] | 4           | Olanzapine         | Metformin (2250) placebo                | 12               | 40 (4)  | BWT            | 0.09              | BPRS ns |
| 7      | Henderson (2007) [14] | 5           | Clozapine          | Sibutramine (15) placebo                | 12               | 10 (0)  | BWT            | 0.31              | PANSS 0.96 |
| 8      | Poyurovsky (2007) [15] | 5           | Olanzapine         | Reboxetine (4) placebo                  | 6                | 31 (9)  | BWT            | 0.013             | SAPS 0.96 |
| 9      | Baptista (2006) [16] | 4           | Olanzapine         | Metformin (1700) placebo                | 14               | 20 (1)  | BWT            | 0.4               | BPRS ns |
| 10     | Henderson (2005) [7] | 4           | Olanzapine         | Sibutramine (15) placebo                | 12               | 19 (3)  | BWT            | 0.009             | PANSS ns |
| 11     | Poyurovsky (2004) [17] | 3           | Olanzapine         | Famotidine (40) placebo                 | 6                | 7 (0)   | BWT            | 0.91              | SAPS 0.54 |
| 12     | Cavazzoni (2003) [18] | 2           | Olanzapine         | Nizatidine (300) placebo                | 16               | 57 (0)  | BWT            | 0.36              | BPRS 0.63 |
| 13     | Poyurovsky (2003) [19] | 3           | Olanzapine         | Reboxetine (4) placebo                  | 6                | 13 (3)  | BWT            | 0.03              | SAPS 0.83 |
| 14     | Poyurovsky (2002) [20] | 3           | Olanzapine         | Fluoxetine (20) placebo                 | 8                | 15 (4)  | BWT            | 0.44              | SAPS 0.83 |
### Table 2: Meta-analysis of topiramate ($n = 99$).

#### (a)

| Number | First author | Concurrent therapy | Adjunctive agent (mg/day; daily max. dose) | Duration (weeks) | $n$ (drop) | Weight reduction | Primary outcome | Secondary outcome | Mean baseline | Mean change | $P$ | Psychiatry evaluation | Mean baseline | Mean change | $P$ |
|--------|--------------|---------------------|---------------------------------------------|------------------|------------|------------------|----------------|------------------|---------------|-------------|-----|-----------------------|---------------|-------------|-----|
| 2      | Narula (2010) [9] | Olanzapine          | Topiramate (100) placebo                     | 12               | 33 (3)     | 20.1             | −2.5           | 0.004            | PANSS         | 102.9       | −71.7       | 0.001        |
| 3      | Afshar (2009) [10] | Clozapine           | Topiramate (300) placebo                     | 8                | 16 (0)     | 23.2             | −2.19          | ≤0.05            | PANSS         | 96.9        | −20         | <0.001       |

#### (b)

| Number | First author | Difference in means | Standard error | Variance | Z value | $P$ value | Difference in means and 95% CI | Relative weight |
|--------|--------------|---------------------|----------------|----------|---------|-----------|-------------------------------|-----------------|
| 2      | Narula (2010) [9] | −2.500             | 0.990          | 0.980    | −2.525  | 0.012     |                               | 69.41           |
| 3      | Afshar (2009) [10] | −2.190             | 1.491          | 2.223    | −1.469  | 0.142     |                               | 30.59           |
| Total  |              | −2.405             | 0.825          | 0.680    | −2.916  | 0.004     | −8.00 − 4.00 − 0.00 4.00 8.00 | 100.00          |

Heterogeneity: $Q = 0.03$; $df = 1; P = 0.86$; $I^2 = 0.00$. 
Table 3: Meta-analysis of sibutramine (n = 58).

(a)

| Number | First author | Concurrent therapy | Adjunctive agent (mg/day, daily max. dose) | Duration (weeks) | n (drop) | Weight reduction | Primary outcome | Secondary outcome | P | Psychiatric evaluation | Mean baseline | Mean change | P | PSANSS | Mean baseline | Mean change | P |
|--------|--------------|-------------------|------------------------------------------|------------------|----------|-----------------|-----------------|-----------------|----|------------------------|--------------|-------------|----|---------|--------------|-------------|----|
| 7      | Henderson (2007) [14] | Clozapine | Sibutramine (15) placebo | 12               | 10 (0) 34 (2) | BWT (kg) | 104.8 102.1 | −19 0.5 | 0.310 | PANSS | 63 62 | 5.3 −4.4 | 0.96 |
| 10     | Henderson (2005) [7] | Olanzapine | Sibutramine (15) placebo | 12               | 19 (3) 18 (3) | BWT (kg) | 102.7 109 | −6.8 3.9 | 0.009 | PANSS | 54.9 57.4 | −1.9 −5.5 | ns |

(b)

| Number | First author | Difference in means | Standard error | Variance | Z value | P value | Difference in means and 95% CI | Relative weight |
|--------|--------------|---------------------|---------------|----------|---------|---------|-------------------------------|-----------------|
| 7      | Henderson (2007) [14] | −1.400 | 1.335 | 1.783 | −1.048 | 0.294 | [−2.342, 0.814] | 37.18 |
| 10     | Henderson (2005) [7] | −2.900 | 1.027 | 1.055 | −2.823 | 0.005 | [−8.00, 4.00] | 62.82 |
| Total  |              | −2.342 | 0.814 | 0.663 | −0.747 | 0.004 | [−8.00, 4.00] | 100.00 |

Heterogeneity: Q = 0.79; df = 1; P = 0.37; I^2 = 0.00.
Table 4: Meta-analysis of metformin (n = 160).

(a)

| Number | First author | Concurrent therapy | Adjunctive agent (mg/day, daily max. dose) | Duration (weeks) | n (drop) | Weight reduction | Primary outcome | Secondary outcome | Mean baseline | Mean change | P | Psychiatric evaluation | Mean baseline | Mean change | P |
|--------|--------------|---------------------|-------------------------------------------|------------------|----------|-----------------|-----------------|-----------------|---------------|-------------|----|------------------------|---------------|-------------|----|
| 5      | Wu (2008) [12] | Olanzapine          | Metformin (750) placebo                    | 12               | 20 (0) 20 (1) | BWT (kg)       | 55.7           | 1.9             | <0.02         | SAPS        | 8.5 | 79 | −6.3 | 0.52 |
| 6      | Baptista (2007) [13] | Olanzapine          | Metformin (2250) placebo                   | 12               | 40 (4) 40 (4) | BWT (kg)       | 66.2           | −1.4            | 0.090        | BPRS        | 15.2 | 14.7 | 1.1  | ns  |
| 9      | Baptista (2006) [16] | Olanzapine          | Metformin (1700) placebo                   | 14               | 20 (1) 20 (2) | BWT (kg)       | 58.3           | 5.5             | 0.4          | BPRS        | 18.3 | 174 | −6.6 | ns  |

(b)

| Number | First author | Difference in means | Standard error | Variance | Z value | P value | Difference in means and 95% CI | Relative weight |
|--------|--------------|---------------------|----------------|----------|---------|---------|-------------------------------|-----------------|
| 5      | Wu (2008) [12] | −5.000             | 2.051          | 4.207    | −2.438  | 0.015   | −8.00 −4.00 0.00 4.00 8.00 100.00 | 6.94            |
| 6      | Baptista (2007) [13] | −1.200             | 0.698          | 0.487    | −1.719  | 0.086   | −3.96 −2.08 0.09 1.48 2.60    | 59.94           |
| 9      | Baptista (2006) [16] | −0.800             | 0.939          | 0.882    | −0.852  | 0.394   | −2.06 −1.30 0.29 1.00 1.77    | 33.12           |
| Total  |              | −1.331             | 0.540          | 0.292    | −2.464  | 0.014   | −8.00 −4.00 0.00 4.00 8.00 100.00 | 100.00          |

Heterogeneity: Q = 3.55; df = 2; P = 0.17; I² = 43.74.
Table 5: Meta-analysis of reboxetine (n = 85).

(a)

| Number | First author | Concurrent therapy | Adjunctive agent (mg/day, daily max. dose) | Duration (weeks) | n (drop) | Weight reduction | Primary outcome | Mean baseline | Mean change | P | Secondary outcome | Mean baseline | Mean change | P |
|--------|--------------|---------------------|--------------------------------------------|------------------|----------|-----------------|----------------|--------------|------------|---|-----------------|--------------|------------|---|
| 8      | Poyurovsky (2007) [15] | Olanzapine | Reboxetine (4) placebo | 6                | 31 (9) 28 (9) | BWT (kg) | 67.1 68.4       | 3.3            | 4.9        | 0.013 | SAPS | 6.4 | −3.2 | 0.96 |
| 13     | Poyurovsky (2003) [19] | Olanzapine | Reboxetine (4) placebo | 6                | 13 (3) 13 (3) | BWT (kg) | 65.8 59.8       | 2.4            | 5.4        | 0.03  | SAPS | 23.2 | −18.4 | 0.83 |

(b)

| Number | First author | Difference in means | Standard error | Variance | Z value | P value | Difference in means and 95% CI | Relative weight |
|--------|--------------|---------------------|---------------|----------|---------|---------|--------------------------------|----------------|
| 8      | Poyurovsky (2007) [15] | −1.600 | 0.624 | 0.389 | −2.564 | 0.010 | −8.00 −4.00 | 81.29 |
| 13     | Poyurovsky (2003) [19] | −3.000 | 1.300 | 1.691 | −2.307 | 0.021 | −3.00 −0.00 | 19.71 |
| Total  |               | −1.862 | 0.563 | 0.316 | −3.310 | 0.001 | −8.00 −4.00 | 100.00 |

Heterogeneity: Q = 0.94; df = 1; P = 0.33; I² = 0.00.
as an antidepressant and antianxiety agent, which has been reported to have effects on weight loss [21]. Lu et al. reported a case significant weight loss treated with reboxetine at 12 mg daily for a total duration of 11 months [22]. Through stimulation of NE activity by the selective NRI, reboxetine is considered to diminish olanzapine induced weight gain [19]. In present study, two clinical trials were examined, and the results were in-line with previous researches at a glance in which reboxetine showed less weight gain than placebo \((z = -3.310, P = 0.001)\). However, the mean weight changes of the reboxetine groups were increased from the baseline (ranged from +2.4 kg to +3.3 kg). That means patients could get obese in spite of taking reboxetine for weight reduction, which reflects that the medication seems ineffective treatment option for weight reduction of patients prescribed atypical antipsychotics [23].

Reboxetine is known as a mediator of enhancing cognitive dysfunction in schizophrenia patients; long-term studies using higher dosages are needed to determine the role of reboxetine as cognitive enhancers in patients with schizophrenia and other disorders associated with cognitive impairments [22, 23]. Conversely, in this review, the reboxetine group did not show statistical difference of psychiatric symptom improvement compared to the placebo group. Though adverse effects were tolerable, seven out of eighty-five participants were withdrawn from the trials due to lack of efficacy. More evidence of its safety profile is warranted before promotions become widely accepted [22].

Sibutramine is a weight loss agent affecting both serotonin and norepinephrine reuptake, which partly mediates activation of the serotonin 5-HT2c receptor that associated with weight loss [7]. In a 16-week double-blind trial, the addition of sibutramine to an ongoing antipsychotic regimen was shown to have no significant differences between groups on mean loss of weight [24]. In this study, sibutramine adjunctive treatments were significantly effective on weight reduction compared to placebo \((z = -2.877, P = 0.004)\). In the research by Henderson et al., the weight reduction in the sibutramine group has shown obvious effects compared to the placebo group \((\text{mean change from baseline}, \ -6.8 \text{ kg versus} \ +3.9 \text{ kg}) [7]\). Though overall adverse effects were tolerable and no subjects were withdrawn from present review for adverse events, systolic blood pressure was increased significantly in the sibutramine group, and one subject in the sibutramine group died during week 10 in this review by undetected coronary artery disease, despite a normal cardiac stress test within a year prior to the study [7].

Since 2002, several cardiovascular adverse events (hypertension, tachycardia, arrhythmias, and myocardial infarction) were reported in sibutramine-treated patients [7,14, 24]. The Sibutramine Cardiovascular Outcomes Trial (SCOUT) confirmed that subjects with preexisting cardiovascular disease (CVD) on long-term treatment with sibutramine had a significantly increased risk for nonfatal myocardial infarction and nonfatal stroke but not cardiovascular death or all-cause mortality [25]. The US Food and Drug Administration (FDA) first stated that the drug should carry a “black box” warning because of an increased risk of stroke and heart attack in patients with a history of CVD. In October 2010, sibutramine was withdrawn from the US market [22].

Metformin is a hepatic-selective insulin sensitizer, which reduces weight, blood glucose, insulin, and hemoglobin Alc (HbA1c) levels in obese nondiabetic adults [12]. It has been demonstrated to improve glycemic control and promotes a moderate weight loss in both diabetic and nondiabetic subjects [11, 13]. Metformin is particularly attractive because of its dual mechanism of decreasing body weight gain and improving insulin sensitivity, both of which are affected by olanzapine [26]. Present review from three clinical trials showed that the weight gain of metformin group was less than the placebo group \((z = -2.464, P = 0.014)\). Adverse effects were tolerable, in accordance with previous researches about metformin, whereas two subjects were withdrawn from the trials for lack of response. Though it was rare, data regarding the metformin indicated potential fatal side effect of lactic acidosis, particularly in elderly and those with compromised renal function, and its new-found association with the accumulation of beta-amyloid, a factor in the pathogenesis of Alzheimer’s disease, alter the risk-benefit ratio in the elderly [4].

Aripiprazole is a partial agonist at D2 dopamine and 5-HT1A serotonin receptors and an antagonist at 5-HT2A and 5-HT2C serotonin receptors. In long-term studies in schizophrenia, aripiprazole treatment has not been associated with a mean increase in body weight from baseline; in some studies, small decreases in mean body weight have been observed [27, 28]. Karunakaran et al. [29] reported an average weight loss of 5.1 kg among patients who had aripiprazole added to decreased doses of clozapine over 34 weeks. Henderson et al. [30] concluded that the addition of aripiprazole to a stable dose of olanzapine was well tolerated and resulted in significant decreases in weight and BMI compared with placebo. There was no significant change in total PANSS or another clinical psychopathology. Present review of aripiprazole \((n = 207)\) was in-line with above trials in terms of weight reduction in which \(-2.5 \text{ kg of mean change from baseline was shown in the aripiprazole group. There were no significant differences in PANSS score changes between groups but Clinical Global Impression Improvement and Investigator’s Assessment Questionnaire scores favored aripiprazole over placebo [30]. On the other hand, the adverse effects were worse than previous trials: ten patients complained about severe adverse effects and three of them developed moderate sinus tachycardia, severe psychotic disorder, and severe auditory hallucinations [28, 29]. Thus, combining aripiprazole and clozapine may be in significant weight reduction to patients suboptimally treated with clozapine, while this has to be balanced against the higher likelihood of the aripiprazole and clozapine combination to induce side effects such as nausea, anxiety, and akathisia [8].

Topiramate has been associated with weight loss as a side effect by reduced appetite related to the mechanism of potentiating GABAergic transmission and antagonism of AMPA glutamate receptors; its precise mechanism remains under investigation [31]. Several researchers have described that topiramate adjunctive treatments appeared to be scarcely effective for reducing weight and clinical symptoms and
even induce exacerbations of symptoms [6, 32]. Other studies reported that topiramate adjunctive treatments led to improvement in psychiatric symptoms, and decrease in body weight, which were generally well tolerated [33]. Present study showed that topiramate adjunctive treatments were effective on weight reduction ($z = -2.916, P = 0.004$) as well as improvement of psychiatric symptoms evaluated by PANSS ($P \leq 0.001$). Adverse effects were mild to moderate in severity with no serious adverse effects evidenced by no treatment withdrawal due to these side effects [9, 10]. Topiramate may prevent olanzapine induced weight gain and adverse metabolic effects [9], and its clinical response (more than 20% reduction in PANSS) is significantly higher than those of control groups (50% versus 12.5%) [10]. Therefore, topiramate adjunctive treatment can be effective in reduction of body weight induced by atypical antipsychotics as well as controlling schizophrenic symptoms [10].

Limitations of this study include that small number of trials have been selected as relevant trials among 131 trials, which may prohibit direct application or generalization of the results. In addition, there is still controversy regarding weight gain and metabolic side effects across available antipsychotic drugs showing distinction between typical and atypical drugs. Thus, in this study, we have focused on the issue related with olanzapine and clozapine, which has evidences of side effects concerning weight gain and metabolic syndrome, which needs conscious deliberation on discourse concerning results of this study.

5. Conclusion

Adjunctive treatments of metformin, sibutramine, topiramate, and aripiprazole are significantly effective to reduce weight for patients receiving atypical antipsychotics. While it presented larger weight reduction, sibutramine is not a choice of option, which was withdrawn from the US market for critical cardiovascular adverse events. Although metformin outperformed other agents that have been studied against placebo, the current evidence is too limited to support its regular clinical use as an adjunctive medication and it needs additional proofs of safety regarding Alzheimer’s disease. Though having several reports related to exacerbation of psychiatric symptoms, topiramate and aripiprazole are more efficacious than other medications in regard to weight reduction and less burden of critical adverse effects as well as being beneficial for clinical improvement. Results of this study provide opportunity to consider adjunctive treatments added to atypical antipsychotics for weight control and/or metabolic syndrome in patients with schizophrenia.

Conflict of Interests

The author declares no conflict of interests in the paper.

References

[1] E. Lévy, C. Agbokou, F. Ferreri, G. Chouinard, and H. C. Margolese, “Topiramate—induced weight loss in schizophrenia: a retrospective case series study,” Canadian Journal of Clinical Pharmacology, vol. 14, no. 2, pp. e234–e239, 2007.
[2] W. K. Kroese, S. J. Hufseisen, B. A. Popadak et al., “H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs,” Neuropsychopharmacology, vol. 28, no. 3, pp. 519–526, 2003.
[3] L. A. Templeman, G. P. Reynolds, B. Arranz, and L. San, “Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis,” Pharmacogenetics and Genomics, vol. 15, no. 4, pp. 195–200, 2005.
[4] L. Maayan, J. Vakhrusheva, and C. U. Correll, “Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis,” Neuropsychopharmacology, vol. 35, no. 7, pp. 1520–1530, 2010.
[5] S. Coodin, “Body mass index in persons with schizophrenia,” Canadian Journal of Psychiatry, vol. 46, no. 6, pp. 549–555, 2001.
[6] M. Muscatello, A. Bruno, G. Pandolfo et al., “Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study,” Journal of Psychopharmacology, vol. 25, no. 5, pp. 667–674, 2011.
[7] D. C. Henderson, X. Fan, P. M. Copeland et al., “A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain,” The American Journal of Psychiatry, vol. 162, no. 5, pp. 954–962, 2005.
[8] W. W. Fleischhacker, M. E. Heikkinen, J.-P. Olié et al., “Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial,” International Journal of Neuropsychopharmacology, vol. 13, no. 8, pp. 1115–1125, 2010.
[9] P. K. Narula, H. S. Rehan, K. E. S. Unni, and N. Gupta, “Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial,” Schizophrenia Research, vol. 118, no. 1–3, pp. 218–223, 2010.
[10] H. Afshar, H. Roohafza, G. Mousavi et al., “Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial,” Journal of Psychopharmacology, vol. 23, no. 2, pp. 157–162, 2009.
[11] T. Baptista, E. Uzcátegui, N. Rangel et al., “Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study,” Psychiatry Research, vol. 159, no. 1-2, pp. 250–253, 2008.
[12] R.-R. Wu, J.-P. Zhao, X.-F. Guo et al., “Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study,” The American Journal of Psychiatry, vol. 165, no. 3, pp. 352–358, 2008.
[13] T. Baptista, N. Rangel, V. Fernández et al., “Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial,” Schizophrenia Research, vol. 93, no. 1–3, pp. 99–108, 2007.
[14] D. C. Henderson, X. Fan, P. M. Copeland et al., “A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain,” Acta Psychiatraca Scandinavica, vol. 115, no. 2, pp. 101–105, 2007.
[15] M. Poyurovsky, C. Fuchs, A. Pashinin et al., “Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated patients,” The Scientific World Journal, 2017.
schizophrenia patients: a double-blind placebo-controlled study,” *Psychopharmacology*, vol. 192, no. 3, pp. 441–448, 2007.

[16] T. Baptista, J. Martínez, A. Lacruz et al., “Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial,” *Canadian Journal of Psychiatry*, vol. 51, no. 3, pp. 192–196, 2006.

[17] M. Poyurovsky, V. Tal, R. Maayan, I. Gil-Ad, C. Fuchs, and A. Weizman, “The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study,” *European Neuropsychopharmacology*, vol. 14, no. 4, pp. 332–336, 2004.

[18] P. Cavazzoni, Y. Tanaka, S. M. Roychowdhury, A. Breier, and D. B. Allison, “Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial,” *European Neuropsychopharmacology*, vol. 13, no. 2, pp. 81–85, 2003.

[19] M. Poyurovsky, I. Isaacs, C. Fuchs et al., “Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study,” *American Journal of Psychiatry*, vol. 160, no. 2, pp. 297–302, 2003.

[20] M. Poyurovsky, A. Pashinian, I. Gil-Ad et al., “Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition,” *The American Journal of Psychiatry*, vol. 159, no. 6, pp. 1058–1060, 2002.

[21] A. Bertani, G. Perna, G. Migliarese et al., “Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study,” *Pharmacopsychiatry*, vol. 37, no. 5, pp. 206–210, 2004.

[22] T. Y.-T. Lu, A. Kupa, G. Easterbrook, and A. A. Mangoni, “Profound weight loss associated with reboxetine use in a 44-year-old woman,” *British Journal of Clinical Pharmacology*, vol. 60, no. 2, pp. 218–220, 2005.

[23] M. Poyurovsky, S. Faragian, C. Fuchs, and A. Pashinian, “Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study,” *The Israel Journal of Psychiatry and Related Sciences*, vol. 46, no. 3, pp. 213–220, 2009.

[24] L. Radulovic, P. Weiden, and D. B. Allison, “A double-blind, placebo-controlled trial of adjunctive sibutramine for obesity in patients with schizophrenia,” in *Proceedings of the Meeting of the New Clinical Drug Evaluation Unit (NCDEU ’02)*, pp. 1–15, Rockville, Md, USA, 2002.

[25] A. J. Scheen, “Sibutramine on cardiovascular outcome,” *Diabetes Care*, vol. 34, no. 2, pp. S114–S119, 2011.

[26] S. K. Praharaj, A. K. Jana, N. Goyal, and V. K. Sinha, “Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis,” *British Journal of Clinical Pharmacology*, vol. 71, no. 3, pp. 377–382, 2011.

[27] R. L. Kolotkin, P. K. Corey-Lisle, R. D. Crosby, H. J. Kan, and R. D. McQuade, “Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care,” *European Psychiatry*, vol. 23, no. 8, pp. 561–566, 2008.

[28] J. W. Newcomer, J. A. Campos, R. N. Marcus et al., “A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine,” *The Journal of Clinical Psychiatry*, vol. 69, no. 7, pp. 1046–1056, 2008.

[29] K. Karunakaran, T. E. Tungaraza, and G. C. Harborne, “Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?” *Journal of Psychopharmacology*, vol. 21, no. 4, pp. 453–456, 2007.

[30] D. C. Henderson, X. Fan, P. M. Copeland et al., “Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients,” *Journal of Clinical Psychopharmacology*, vol. 29, no. 2, pp. 165–169, 2009.

[31] E. Ben-Menachem, M. Axelsen, E. H. Johanson, A. Stage, and U. Smith, “Predictors of weight loss in adults with topiramate-treated epilepsy,” *Obesity Research*, vol. 11, no. 4, pp. 556–562, 2003.

[32] G. Gobbi, P.-O. Gaudreau, and N. Leblanc, “Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis,” *Journal of Clinical Psychopharmacology*, vol. 26, no. 5, pp. 467–473, 2006.

[33] M. K. Hahn, G. Remington, D. Bois, and T. Cohn, “Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects,” *Journal of Clinical Psychopharmacology*, vol. 30, no. 6, pp. 706–710, 2010.